Efficacy and safety of immunotherapy plus chemotherapy in advanced or metastatic pulmonary large-cell neuroendocrine carcinoma
Immunotherapy plus chemotherapy significantly improved OS compared with chemotherapy in LCNEC, with a tolerable safety profile without life-threatening adverse events. Immunotherapy plus chemotherapy may be an effective treatment option for patients with advanced LCNEC.
Authors
- Xue Dong (ORCID: https://orcid.org/0009-0003-1233-8674)
- Yali Xu (ORCID: https://orcid.org/0000-0002-4945-6135)
- Yintao Li (ORCID: https://orcid.org/0000-0003-4665-8900)
- Ying Li (ORCID: https://orcid.org/0009-0006-8813-133X)
- H. Zhang (ORCID: https://orcid.org/0009-0002-9200-3710)
- Ruyue Li (ORCID: https://orcid.org/0009-0006-2086-4131)
- Xiujing Yao (ORCID: https://orcid.org/0009-0006-8420-9814)
Institutions
- Weifang Medical University (CN)
- Shandong Tumor Hospital (CN)
- Shandong Provincial Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1007/s12672-025-02071-8
- Citations
- 4
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province